Eli Lilly: Hold $1000 Target Ahead Of Q3 Earnings, New Trading Range (NYSE:LLY)

New Trading Range

Eli Lilly and company continue to hold steady on their $1000 price target ahead of their Q3 earnings report on November 3rd. However, due to recent performance, LLY has adjusted its trading range from $312.69 to $357.59.

Analyst Recommendations

Analysts at SVB Securities maintain their “outperform” rating for Eli Lilly and Company. The firm believes that LLY is well-positioned for long-term growth due to its strong pipeline of new drugs and therapies.

Technical Analysis

Technically, LLY has been trading in a range between $312.69 and $357.59 since August. The stock recently broke out of this range and is now testing the $360 resistance level. If LLY can break above this level, it could continue to move higher towards its $1000 price target.

Key Takeaways

• Eli Lilly and company maintain a $1000 price target ahead of Q3 earnings.
• Analysts at SVB Securities maintain their “outperform” rating for LLY.
• Technically, LLY has been trading in a range between $312.69 and $357.59 since August.
• If LLY can break above the $360 resistance level, it could continue to move higher towards its $1000 price target.